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As mast cells have been implicated in cutaneous
repair processes, we have examined the ability of
human mast cells to produce important epithelial
and ®broblast growth factors or to stimulate the pro-
duction of such factors in dermal ®broblasts.
Isolated, highly puri®ed human dermal mast cells
and human leukemic mast cells were examined for
mRNA and partly also for protein expression of
these molecules as such or after preincubation with
interleukin-4, stem cell factor, or with phorbol
myristate acetate. In addition, mast cells were
studied for their ability to induce ®broblast growth
factor 2 and ®broblast growth factor 7 secretion
from dermal ®broblasts. Both dermal and leukemic
mast cells expressed ®broblast growth factor 2, ®bro-
blast growth factor 7, and heparin-binding epidermal
growth factor, but not hepatocyte growth factor at
mRNA level, and dermal mast cells expressed ®bro-
blast growth factor 10 in addition. At protein level,
spontaneous ®broblast growth factor 2 secretion was
noted that was markedly enhanced by phorbol
myristate acetate, whereas no ®broblast growth fac-
tor 7 protein was detected under these conditions.
Instead, human mast cell-1 supernatants induced
enhanced ®broblast growth factor 7 secretion from
dermal ®broblasts, with phorbol-myristate-acetate-
stimulated supernatants being more effective. This
effect could be reproduced with histamine and was
H1-receptor mediated. Tryptase was ineffective but
stimulated instead ®broblast growth factor 2 secre-
tion from ®broblasts. These data demonstrate for the
®rst time the ability of mast cells to express and/or
secrete several growth factors of the ®broblast
growth factor family as well as heparin-binding epi-
dermal growth factor directly or indirectly via stimu-
lation of ®broblasts, underlining the potentially
pivotal role of these cells during human tissue repair
and homeostasis. Key words: FGF/HB-EGF/HGF/
histamine/tryptase. J Invest Dermatol 118:391±395, 2002
I
n the past, mast cells have been viewed primarily as effector
cells of immediate type hypersensitivity reactions. There is
growing evidence, however, that mast cells not only induce
potentially harmful pathologic reactions, but also play a
fundamental role in tissue homeostasis, remodeling, and
repair (Metcalfe et al, 1997; Artuc et al, 1999). Mast cells store and
release various potent mediators, in particular histamine, proteases,
lipid mediators, and cytokines through which they can in¯uence
different stages of cutaneous wound healing. Furthermore, mast
cells of various origins have been described as expressing and/or
secreting speci®c growth factors, namely transforming growth
factor b, stem cell factor (SCF), nerve growth factor, granulocyte±
macrophage colony stimulating factor (GM-CSF), platelet-derived
growth factor, vascular endothelial growth factor, and ®broblast
growth factor 2 (FGF-2), through which they might directly
promote growth and differentiation of ®broblasts, keratinocytes,
and other resident tissue cells. Conversely, mast cell growth is
in¯uenced by ®broblast and keratinocyte derived growth factors
such as SCF, nerve growth factor, and granulocyte±macrophage
colony stimulating factor (Grabbe et al, 1994; Metcalfe et al, 1997;
Artuc et al, 1999; Henz et al, 2001).
Several of the at least 18 members of the FGF family have
recently been shown to play a pivotal role in wound healing and/or
epidermal differentiation (Werner, 1998). This holds in particular
for FGF-7, which is also called keratinocyte growth factor.
Keratinocyte growth is furthermore regulated by pluripotent
growth factors such as hepatocyte growth factor (HGF) (Davis-
Fleischer and Besner, 1998) and heparin-binding epidermal growth
factor (HB-EGF) (Marikovsky et al, 1996; Raab and Klagsbrun,
1997). Interestingly, FGF-7 synthesis by ®broblasts can be induced
by keratinocyte derived factors (Maas-Szabowski et al, 1999),
suggesting that resident tissue cells may well be able to in¯uence
keratinocyte proliferation and/or differentiation by stimulating
growth factor production in dermal ®broblasts. A network of
cellular interactions might thus be operative to regulate cutaneous
homeostasis and repair.
In order to shed further light on these potential interactions, we
have examined here the ability of human dermal mast cells to
produce major members of the FGF family (FGF-2, FGF-7, FGF-
10) as well as HGF and HB-EGF. Furthermore, we have explored
the effect of mast cell supernatants and of major mediators stored
within mast cells for their effect on the production of selected
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members of the FGF family by ®broblasts. The data show that mast
cells represent indeed a potential source of several of the molecules
examined and that mast cells can also stimulate the production of
such molecules in dermal ®broblasts.
MATERIALS AND METHODS
Isolation and culture of human dermal mast cells The source of
skin tissue and the isolation of human dermal mast cells have been
described previously (GruÈtzkau et al, 2000). Brie¯y, the epidermis was
enzymatically detached from the dermis by an overnight incubation with
dispase (Boehringer, Mannheim, Germany) at a concentration of 1 mg
per ml. The dermis was then cut into small pieces and incubated with
collagenase type IV (Worthington Biochemistry, Freehold) for up to
120 min at 37°C. Thereafter, cells were recovered, washed, and cultured
overnight in standard conditions in RPMI 1640 medium (Biochrom,
Berlin, Germany) supplemented with 10% fetal bovine serum (FBS;
Biochrom). Mast cells were further enriched by positive magnetic
selection using the MACS microbeads technology (Milteny Biotec,
Bergisch Gladbach, Germany). For that purpose, the dermal cell
suspension was incubated for 30 min with the monoclonal antibody
YB5.B8, which recognizes the c-kit receptor (CD 117) (kindly provided
by Dr. L. Ashman, Adelaide, Australia). After washing with phosphate-
buffered saline (PBS) supplemented with 1% bovine serum albumin
(BSA) and ethylenediamine tetraacetic acid (EDTA), a second incubation
was done with a MACS-conjugated goat antimouse polyclonal serum
(Milteny). Labeled cells were separated by passage over a large cell
separation column (Milteny), which was placed in a magnetic ®eld. Cells
were then washed thrice and, after removing the column from the
separator, retained cells were eluted with 500 ml PBS (supplemented
with 1% BSA and EDTA). Purity of mast cells was over 90%, as
measured by ¯ow cytometry. Mast cells were identi®ed by
immunostaining for the c-kit receptor (monoclonal antibody YB5.B8,
see above) and the a-chain of the high af®nity IgE-receptor (monoclonal
antibody 29C6, kindly provided by Dr. J. Hakimi, Hoffman La Roche)
and by toluidine blue staining at pH 0.5. Viability of mast cells was over
95%, as determined by exclusion of trypan blue.
Dermal mast cells were cultured in RPMI 1640 supplemented with
FBS and antibiotics (penicillin and streptomycin, both from Biochrom)
for several days. For determination of growth factor expression, cells
were additionally stimulated for 24 h (protein secretion) with SCF
(50 ng per ml) (Preprotech, Rocky Hill, NJ) or interleukin-4 (IL-4; 5 ng
per ml), or a combination of SCF and IL-4, and compared to
unstimulated controls. Growth factors were measured in cell supernatants
as well as in homogenates. Cells were sonicated for homogenization.
Isolation and culture of dermal ®broblasts Fibroblast cultures were
obtained from the dermis of juvenile human foreskin, as described
previously (YlaÈ-Outinen et al, 1998). Brie¯y, dermis was cut into small
pieces and incubated in Dulbecco's modi®ed Eagle's medium (DMEM)
supplemented with antibiotics (streptomycin and penicillin) and 10%
FBS. Dermal ®broblasts grew from these explants within a week. Cells
were thereafter trypsinized and subcultured in the medium described
above. Only cells cultured from passages two to four were used for the
experiments.
Culture of the human mast cell line HMC-1 Cells from the human
mast cell line HMC-1 (kindly provided by Dr. J.H. Butter®eld,
Rochester) were cultured in Iscove's medium (Biochrom) containing
10% FBS, 10 mM monothioglycerol (Sigma, Deisenhofen, Germany),
and antibiotics (streptomycin and penicillin) (Butter®eld et al, 1988).
Cells cultured in order to measure growth factor release were stimulated
by phorbol myristate acetate (PMA) at increasing concentrations (3, 5,
10, 50, and 100 ng per ml) for 24 h or kept unstimulated as controls.
Growth factors were determined in cell supernatants as well as in cell
homogenates obtained by soni®cation.
HMC-1 supernatants for the stimulation of dermal ®broblasts were
derived from cells adjusted to 1 3 106 per ml and kept in serum-free
medium alone or after addition of PMA (40 mg per ml) for 24 h.
Isolation of RNA and reverse transcription polymerase chain
reaction (RT-PCR) For RT-PCR, total RNA was isolated from
puri®ed human mast cells and HMC-1 cells using the RNeasy system
(Qiagen, Hilden, Germany). Total RNA was treated with RNAse free
DNAse (Boehringer) to digest genomic DNA. After isopropanol
precipitation, RNA was transcribed to cDNA by M-MMVL reverse
transcriptase (Gibco, Eggenstein, Germany) according to the manu-
facturer's instructions. The resulting cDNA was ampli®ed using growth
factor sequence speci®c primers in 30 cycles of PCR (95°C for 45 s,
65°C for 45 s, and 72°C for 45 s), followed by a 10 min extension step
at 72°C. Primers for RT-PCR were selected using Primer 3 software.
The following oligonucleotides were used as primers for the PCR
reactions: FGF-2, 5¢-AGGAGTGTGTGCTAACCGTTA-3¢, 5¢-GCA-
GACATTGGAAGAAAAAG-3¢; FGF-5, 5¢-TCTTCCTCTTCTG-
CCTCCT-3¢, 5¢-TCCTACAATCCCCTGAGACA 3¢; FGF-7, 5¢-
AAATCAGGACAGTGGCAGTT-3¢, 5¢-CTTTCTTCGTTTTTT-
TTCCTC-3¢; FGF-10, 5¢-TGTCACCTGCCAAGCCCTT-3¢, 5¢-
TACGGGCAGTTCTCCTTCTT-3¢; HGF, 5¢-AGAAACTGCATC-
ATCGGT-3¢, 5¢-AAGAATTTGTGCCGGTGTGGT-3¢; HB-EGF, 5¢-
CAGTTGCCGTCTAGGATTGG-3¢, 5¢-GGAGCATATGGAATT-
TAACCG-3¢.
Stimulation of ®broblasts Fibroblasts of passages two to four were
seeded into culture dishes of 10 cm diameter at a density of 10,000 cells
per ml and grown to con¯uence in DMEM. After removal of culture
medium, cells were washed with PBS and subsequently incubated for the
following 24 h in FBS-free DMEM. Thereafter, ®broblasts were
incubated for another 24 h in buffer alone or stimulated with mast cell
(HMC-1) supernatants, histamine (Sigma) 10±4±10±9 M, or tryptase
(0.05±5 mU) (Promega, Mannheim, Germany). After incubation,
®broblast supernatants were examined for the release of growth factors.
In order to determine which type of histamine receptor was respon-
sible for the induction of growth factor synthesis in ®broblasts, cells were
preincubated with speci®c H1- or H2-receptor antagonists (descarbo-
ethoxyloratadine, from Schering, Kenilworth, NJ, and famotidine, from
Sigma at 10±6 to 10±8, each) for 30 min prior to stimulation with
histamine (10±6 M).
Detection of growth factors at protein level FGF-2 and FGF-7
were assayed using a commercial enzyme-linked immunosorbent assay
(ELISA) kit (RD-Systems, Wiesbaden, Germany), according to the
manufacturer's instructions. HB-EGF and FGF-10 were not tested at
protein level because no assays or suitable antibodies are commercially
available.
RESULTS
Expression of growth factors in human dermal mast
cells RT-PCR of mRNA derived from freshly isolated human
dermal mast cells (Fig 1) as well as from routinely kept HMC-1
cells (data not shown) revealed positive signals for FGF-2, FGF-7,
and HB-EGF. Dermal mast cells expressed in addition FGF-10
mRNA, which could not be found in HMC-1 cells. In both types
of mast cells, the signal for HB-EGF was particularly prominent,
and that for HGF was not found at all.
At the protein level, FGF-2 (Fig 2), but not FGF-7 (not shown),
was also detected in dermal mast cell supernatants and homo-
genates. Stimulation of dermal mast cells with IL-4 and SCF alone
or in combination did not increase the expression of FGF-2 in
supernatants or cell homogenates (Fig 2), nor did it induce FGF-7
protein production (not shown). In HMC-1 cell supernatants
(Fig 3), low level FGF-2 was secreted already in the presence of
buffer alone. A marked, concentration-dependent increase
occurred when the cells were activated with PMA, with an
Figure 1. Human dermal mast cells express various growth
factors. Representative agarose gel showing ampli®cation products of
mRNA encoding FGF-2, FGF-7, FGF-10, and HB-EGF. No positive
signals were noted for FGF-5 and HGF.
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optimal response at 10 ng per ml and no further increase at higher
concentrations (Fig 3). No expression of FGF-7 protein was
observed under these conditions in supernatants or homogenates
(not shown).
Release of FGF-2 and FGF-7 from human dermal ®broblasts
after stimulation with mast cell mediators As FGF-7 was not
released by mast cells, we examined next whether mast cells might
secondarily contribute to growth factor production via stimulation
of ®broblasts. These studies were restricted to FGF-7 as FGF-2 is
already present in HMC-1 cell supernatants, and commercial assays
for the other growth factors were not available. Surprisingly,
HMC-1 supernatants markedly increased release of FGF-7 from
dermal ®broblasts; this could be further augmented by prior
activation of HMC-1 cells with PMA (40 ng per ml) and even
exceeded the amount of FGF-7 secreted by PMA-stimulated
®broblasts (Fig 4).
In order to identify which factors in mast cells might be
responsible for this augmentation, ®broblasts were incubated with
the mast cell mediators tryptase and histamine both of which are
present in mast cells in a preformed state. Addition of tryptase at
0.05±5 mU caused a dose-dependent enhancement of FGF-2
release, with an optimum at 0.5 mU tryptase, whereas the release of
FGF-7 was unaltered under these conditions (Fig 5).
In contrast, histamine, at 10±4±10±9 M, caused the reverse effect,
namely a dose-dependent enhancement of FGF-7 release, whereas
no such effects were noted with FGF-2 (Fig 6). There was even a
suggestion of decreased FGF-2 release in the presence of high
concentrations of histamine, but this effect was not further studied
(Fig 6).
The histamine-induced augmentation of FGF-7 release, with
histamine set at 10±6 M, could be completely blocked by
preincubation with the potent H1-histamine-receptor antagonist
descarboethoxyloratadine 10±6±10±8 M, whereas preincubation
with the speci®c H2-histamine-receptor antagonist famotidine
(10±6±10±8 M) had no effect (Fig 7), indicating that this novel
histamine action is mediated via H1 receptors.
DISCUSSION
This study shows for the ®rst time that human dermal mast cells
selectively express mRNA for important epithelial and connective
tissue growth factors, namely FGF-2, FGF-7, FGF-10, and HB-
EGF, but not HGF. Expression of FGF-2 at protein level, as
previously reported by others (Reed et al, 1995), could be
con®rmed, whereas FGF-7 could not be detected at protein level
under the conditions employed. Reasons might be a lack of FGF-7
translation into protein within mast cells, a requirement for speci®c
stimuli to induce this translation, which was not studied here, or
the masking of FGF-7 by binding molecules such as heparin. The
latter explanation is unlikely, however, as this situation must have
also prevailed in studies of FGF-7 secretion from ®broblasts in the
presence of mast cell supernatants.
Figure 3. HMC-1 cells express FGF-2 protein, and FGF-2
expression is enhanced by PMA. FGF-2 was detected in cell
supernatants by ELISA. A low basal secretion of FGF-2 protein could be
markedly and dose-dependently enhanced by stimulation with PMA,
reaching a maximum at 10 mg per ml PMA added. Data are given as
mean 6 SEM, n = 3.
Figure 4. Expression of FGF-7 protein by human dermal
®broblasts can be stimulated by mast cell supernatants. FGF-7 was
detected in ®broblast supernatants by ELISA: (A) controls; (B) ®broblasts
stimulated with PMA; (C) ®broblasts stimulated with supernatants
derived from unstimulated HMC-1 cells; (D) ®broblasts stimulated with
supernatants derived from HMC-1 cells stimulated with PMA (40 mg per
ml). Data are given as mean 6 SEM, n = 3.
Figure 5. Tryptase stimulates FGF-2 secretion by human dermal
®broblasts. FGF-2 and FGF-7 were detected in ®broblast supernatants
by ELISA. Tryptase (0.05±5 mU) stimulated FGF-2 secretion by human
dermal ®broblasts with a maximum at 0.5 mU, but had no effect on
FGF-7 secretion. Data are given as mean 6 SEM (FGF-7, n = 3;
FGF-2, n = 5). Statistical analyses were performed using Student's two-
tailed t test. *p < 0.05 vs control; **p < 0.005 vs control.
Figure 2. Human dermal mast cells express FGF-2 protein.
FGF-2 was detected in cell supernatants as well as in homogenates by
ELISA. FGF-2 could not be further augmented by stimulation with IL-4
(5 ng per ml) or SCF (50 ng per ml) or a combination of both. Data are
given as mean 6 SEM, n = 3.
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A second novel ®nding of this study is the detection of the ability
of mast cells to induce the differential secretion of FGF-7 and
FGF-2 from human dermal ®broblasts. As a possible mechanism, it
could furthermore be shown that FGF-7 secretion is mediated by
histamine. This biogenic amine has in the past been shown to
induce ®broblast Ca2+ entry (Ogata et al, 1999), CD54 expression
(Cagnoni et al, 2000), proliferation (Leonardi et al, 1999), and
collagen gel contraction (Takeda et al, 1997) via the H1 receptor,
and proliferation (Leonardi et al, 1999), type I collagen synthesis
(Takeda et al, 1997), and chemotaxis (Kupietzky and Levi-Schaffer,
1996; Leonardi et al, 1999) via the H2 receptor. Our data, showing
H1-receptor-mediated FGF-7 synthesis from human dermal
®broblasts, thus suggest a novel pathway for the H1-mediated
proliferative effect of histamine on ®broblasts. These ®ndings may
also provide an explanation for the in vivo proliferative effect of
histamine on epidermal cells that we have previously reported in
mice (Maurer et al, 1997), and they may be of pathologic
signi®cance in cutaneous wound healing. During the process of
wound healing, mast cell granules are released into the tissue, are
phagocytized by ®broblasts and endothelial cells, and can thus
contribute to persistently increased tissue histamine levels (Artuc
et al, 1999). It is thus likely that, after wounding, histamine
enhances not only the concomitant in¯ammatory reaction, but ±
via the induction of FGF-7 synthesis ± also the proliferation and
differentiation of ®broblasts and keratinocytes.
Mast cell activation during wound healing leads also to a
signi®cant rise in tissue tryptase (Hermes et al, 2000). Tryptase is
known to potentially in¯uence ®broblasts and extracellular matrix
formation in wound healing in various ways, including a mitogenic
effect on ®broblasts but not keratinocytes (Ruoss et al, 1991; Cairns
and Walls, 1997; Gruber et al, 1997; Algermissen et al, 1999). As
PAR-2 activating peptides mimicked these effects in lung
®broblasts, tryptase-dependent ®broblast proliferation might be
mediated via this receptor (Akers et al, 2000). This signaling
pathway, however, has been reported to be restricted to lung
®broblasts and has been explicitly excluded for the proliferative
action of tryptase on dermal ®broblasts (Akers et al, 2000). Our
®ndings therefore suggest an alternative mechanism of tryptase
action on dermal ®broblasts, namely via stimulation of FGF-2
synthesis, which in turn can promote ®broblast proliferation in an
autocrine way.
FGF-2 has additionally been shown to play a role in ®brosis. The
data provided are, however, controversial. Whereas FGF-2 inhibits
collagen synthesis by dermal ®broblasts in vitro (Tan et al, 1993), it is
overexpressed in ®brotic disease such as hypertrophic scars, keloids
(Akimoto et al, 1999), or Dupuytren's contracture (Gonzalez et al,
1992). Overexpression, though, does not necessarily imply a
stimulatory action. FGF-2 may also function as a regulator of
collagen synthesis and prevent excessive collagen production
induced by other growth factors. Interestingly, mast cell derived
tryptase, which induces FGF-2 secretion from dermal ®broblasts,
has the ability to promote collagen synthesis itself via unknown
mechanisms. It is thus possible that tryptase-induced collagen
synthesis may depend on FGF-2, or ± when FGF-2 really turns out
to act anti®brotically ± that tryptase and FGF-2 may establish a
regulative mechanism for the control of the amount of collagen
production.
Taken together, our data provide insights into new aspects for a
role of mast cells in cutaneous wound healing and epidermal
differentiation. Among various other mechanisms, mast cells seem
to in¯uence the complex processes of wound healing and tissue
homeostasis either through the synthesis and release of growth
factors themselves, or via the stimulation of growth factor release by
dermal ®broblasts. Especially the latter observation provides a
completely new aspect of mast cell function. Further investigations
will have to clarify more details of this mast cell±®broblast
interaction, e.g., the signaling pathways of tryptase and histamine,
and the stimulation of additional growth factors via these
molecules.
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